Trending topics
#
Bonk Eco continues to show strength amid $USELESS rally
#
Pump.fun to raise $1B token sale, traders speculating on airdrop
#
Boop.Fun leading the way with a new launchpad on Solana.
Why?
I doubt the answer is weight loss. Consider 2 other drugs for diabetes: DPP-4 and SGLT-2 inhibitors
GLP-1RAs are associated with less Alzheimer's vs. DPP-4is:
But not SGLT-2is:
Neither generates much weight loss, but SGLT-2is match GLP-1RAs on glycemic benefits
16 hours ago
The evidence that GLP-1 drugs can protect from cognitive decline keeps rolling out.
Now, we have a meta-analysis of trials showing that these drugs provide clinically meaningful improvements in the rate of cognitive decline compared to placebo or other, conventional treatment.
So, at least in this propensity score- or age-matched data, there's no reason to chalk the benefit up to the weight loss effects.
This is a hint though, not definitive. Another hint is that benefits were observed in short trials, meaning likely before significant weight loss.
We can be doubly certain about that last hint because diabetics tend to lose less weight than non-diabetics, and all of the observed benefit has so far been observed in diabetic cohorts, not non-diabetic ones (though those directionally show benefits).
Anyway, trials needed!
14.83K
Top
Ranking
Favorites